1
|
Chedik L, Baybekov S, Cosnier F, Marcou G, Varnek A, Champmartin C. An update of skin permeability data based on a systematic review of recent research. Sci Data 2024; 11:224. [PMID: 38383523 PMCID: PMC10881585 DOI: 10.1038/s41597-024-03026-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Accepted: 01/30/2024] [Indexed: 02/23/2024] Open
Abstract
The cutaneous absorption parameters of xenobiotics are crucial for the development of drugs and cosmetics, as well as for assessing environmental and occupational chemical risks. Despite the great variability in the design of experimental conditions due to uncertain international guidelines, datasets like HuskinDB have been created to report skin absorption endpoints. This review updates available skin permeability data by rigorously compiling research published between 2012 and 2021. Inclusion and exclusion criteria have been selected to build the most harmonized and reusable dataset possible. The Generative Topographic Mapping method was applied to the present dataset and compared to HuskinDB to monitor the progress in skin permeability research and locate chemotypes of particular concern. The open-source dataset (SkinPiX) includes steady-state flux, maximum flux, lag time and permeability coefficient results for the substances tested, as well as relevant information on experimental parameters that can impact the data. It can be used to extract subsets of data for comparisons and to build predictive models.
Collapse
Affiliation(s)
- Lisa Chedik
- Institut national de recherche et de sécurité pour la prévention des accidents du travail et des maladies professionnelles (INRS), Dept Toxicologie et Biométrologie, 1 rue du Morvan, 54519, Vandoeuvre-lès-Nancy, France.
| | - Shamkhal Baybekov
- Laboratoire de Chémoinformatique UMR 7140 CNRS, Institut Le Bel, University of Strasbourg, 4 Rue Blaise Pascal, 67081, Strasbourg, France
| | - Frédéric Cosnier
- Institut national de recherche et de sécurité pour la prévention des accidents du travail et des maladies professionnelles (INRS), Dept Toxicologie et Biométrologie, 1 rue du Morvan, 54519, Vandoeuvre-lès-Nancy, France
| | - Gilles Marcou
- Laboratoire de Chémoinformatique UMR 7140 CNRS, Institut Le Bel, University of Strasbourg, 4 Rue Blaise Pascal, 67081, Strasbourg, France
| | - Alexandre Varnek
- Laboratoire de Chémoinformatique UMR 7140 CNRS, Institut Le Bel, University of Strasbourg, 4 Rue Blaise Pascal, 67081, Strasbourg, France
| | - Catherine Champmartin
- Institut national de recherche et de sécurité pour la prévention des accidents du travail et des maladies professionnelles (INRS), Dept Toxicologie et Biométrologie, 1 rue du Morvan, 54519, Vandoeuvre-lès-Nancy, France
| |
Collapse
|
2
|
Schlich M, Musazzi UM, Campani V, Biondi M, Franzé S, Lai F, De Rosa G, Sinico C, Cilurzo F. Design and development of topical liposomal formulations in a regulatory perspective. Drug Deliv Transl Res 2021; 12:1811-1828. [PMID: 34755281 PMCID: PMC8577404 DOI: 10.1007/s13346-021-01089-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/25/2021] [Indexed: 01/29/2023]
Abstract
The skin is the absorption site for drug substances intended to treat loco-regional diseases, although its barrier properties limit the permeation of drug molecules. The growing knowledge of the skin structure and its physiology have supported the design of innovative nanosystems (e.g. liposomal systems) to improve the absorption of poorly skin-permeable drugs. However, despite the dozens of clinical trials started, few topically applied liposomal systems have been authorized both in the EU and the USA. Indeed, the intrinsic complexity of the topically applied liposomal systems, the higher production costs, the lack of standardized methods and the more stringent guidelines for assessing their benefit/risk balance can be seen as causes of such inefficient translation. The present work aimed to provide an overview of the physicochemical and biopharmaceutical characterization methods that can be applied to topical liposomal systems intended to be marketed as medicinal products, and the current regulatory provisions. The discussion highlights how such methodologies can be relevant for defining the critical quality attributes of the final product, and they can be usefully applied based on the phase of the life cycle of a liposomal product: to guide the formulation studies in the early stages of development, to rationally design preclinical and clinical trials, to support the pharmaceutical quality control system and to sustain post-marketing variations. The provided information can help define harmonized quality standards able to overcome the case-by-case approach currently applied by regulatory agencies in assessing the benefit/risk of the topically applied liposomal systems.
Collapse
Affiliation(s)
- Michele Schlich
- Dipartimento Di Scienze Della Vita E Dell'Ambiente, Sezione Scienze del Farmaco, Università Di Cagliari, via Ospedale 72, 09124, Cagliari, Italy.,Laboratory of Nanotechnology for Precision Medicine, Istituto Italiano Di Tecnologia, via Morego 30, 16163, Genoa, Italy
| | - Umberto M Musazzi
- Department of Pharmaceutical Sciences, Università Degli Studi Di Milano, via G. Colombo 71, 20133, Milan, Italy
| | - Virginia Campani
- Dipartimento Di Farmacia, Università Degli Studi Di Napoli Federico II, via D. Montesano 49, 80131, Naples, Italy
| | - Marco Biondi
- Dipartimento Di Farmacia, Università Degli Studi Di Napoli Federico II, via D. Montesano 49, 80131, Naples, Italy
| | - Silvia Franzé
- Department of Pharmaceutical Sciences, Università Degli Studi Di Milano, via G. Colombo 71, 20133, Milan, Italy
| | - Francesco Lai
- Dipartimento Di Scienze Della Vita E Dell'Ambiente, Sezione Scienze del Farmaco, Università Di Cagliari, via Ospedale 72, 09124, Cagliari, Italy
| | - Giuseppe De Rosa
- Dipartimento Di Farmacia, Università Degli Studi Di Napoli Federico II, via D. Montesano 49, 80131, Naples, Italy
| | - Chiara Sinico
- Dipartimento Di Scienze Della Vita E Dell'Ambiente, Sezione Scienze del Farmaco, Università Di Cagliari, via Ospedale 72, 09124, Cagliari, Italy
| | - Francesco Cilurzo
- Department of Pharmaceutical Sciences, Università Degli Studi Di Milano, via G. Colombo 71, 20133, Milan, Italy.
| |
Collapse
|
3
|
Systems of conductive skin for power transfer in clinical applications. EUROPEAN BIOPHYSICS JOURNAL: EBJ 2021; 51:171-184. [PMID: 34477935 PMCID: PMC8964546 DOI: 10.1007/s00249-021-01568-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Revised: 07/29/2021] [Accepted: 08/12/2021] [Indexed: 11/03/2022]
Abstract
The primary aim of this article is to review the clinical challenges related to the supply of power in implanted left ventricular assist devices (LVADs) by means of transcutaneous drivelines. In effect of that, we present the preventive measures and post-operative protocols that are regularly employed to address the leading problem of driveline infections. Due to the lack of reliable wireless solutions for power transfer in LVADs, the development of new driveline configurations remains at the forefront of different strategies that aim to power LVADs in a less destructive manner. To this end, skin damage and breach formation around transcutaneous LVAD drivelines represent key challenges before improving the current standard of care. For this reason, we assess recent strategies on the surface functionalization of LVAD drivelines, which aim to limit the incidence of driveline infection by directing the responses of the skin tissue. Moreover, we propose a class of power transfer systems that could leverage the ability of skin tissue to effectively heal short diameter wounds. In this direction, we employed a novel method to generate thin conductive wires of controllable surface topography with the potential to minimize skin disruption and eliminate the problem of driveline infections. Our initial results suggest the viability of the small diameter wires for the investigation of new power transfer systems for LVADs. Overall, this review uniquely compiles a diverse number of topics with the aim to instigate new research ventures on the design of power transfer systems for IMDs, and specifically LVADs.
Collapse
|
4
|
Moniz T, Costa Lima SA, Reis S. Human skin models: From healthy to disease-mimetic systems; characteristics and applications. Br J Pharmacol 2020; 177:4314-4329. [PMID: 32608012 PMCID: PMC7484561 DOI: 10.1111/bph.15184] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Revised: 06/15/2020] [Accepted: 06/18/2020] [Indexed: 12/17/2022] Open
Abstract
Skin drug delivery is an emerging route in drug development, leading to an urgent need to understand the behaviour of active pharmaceutical ingredients within the skin. Given, As one of the body's first natural defences, the barrier properties of skin provide an obstacle to the successful outcome of any skin drug therapy. To elucidate the mechanisms underlying this barrier, reductionist strategies have designed several models with different levels of complexity, using non-biological and biological components. Besides the detail of information and resemblance to human skin in vivo, offered by each in vitro model, the technical and economic efforts involved must also be considered when selecting the most suitable model. This review provides an outline of the commonly used skin models, including healthy and diseased conditions, in-house developed and commercialized models, their advantages and limitations, and an overview of the new trends in skin-engineered models.
Collapse
Affiliation(s)
- Tânia Moniz
- LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de FarmáciaUniversidade do PortoPortoPortugal
| | - Sofia A. Costa Lima
- LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de FarmáciaUniversidade do PortoPortoPortugal
| | - Salette Reis
- LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de FarmáciaUniversidade do PortoPortoPortugal
| |
Collapse
|
5
|
Ren P, Yang C, Lofchy LA, Wang G, Chen F, Simberg D. Establishing In Situ Closed Circuit Perfusion of Lower Abdominal Organs and Hind Limbs in Mice. J Vis Exp 2020. [PMID: 32865531 DOI: 10.3791/60847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
Ex vivo perfusion is an important physiological tool to study the function of isolated organs (e.g. liver, kidneys). At the same time, due to the small size of mouse organs, ex vivo perfusion of bone, bladder, skin, prostate, and reproductive organs is challenging or not feasible. Here, we report for the first time an in situ lower body perfusion circuit in mice that includes the above tissues, but bypasses the main clearance organs (kidney, liver, and spleen). The circuit is established by cannulating the abdominal aorta and inferior vena cava above the iliac artery and vein and cauterizing peripheral blood vessels. Perfusion is performed via a peristaltic pump with perfusate flow maintained for up to 2 h. In situ staining with fluorescent lectin and Hoechst solution confirmed that the microvasculature was successfully perfused. This mouse model can be a very useful tool for studying pathological processes as well as mechanisms of drug delivery, migration/metastasis of circulating tumor cells into/from the tumor, and interactions of immune system with perfused organs and tissues.
Collapse
Affiliation(s)
- Ping Ren
- Department of Thoracic Surgery, The First Hospital of Jilin University; The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus; Key Laboratory of Zoonoses Research, Ministry of Education, Jilin University
| | - Chunyan Yang
- The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus; Department of Cardiology, China-Japan Union Hospital of Jilin University
| | - Laren A Lofchy
- The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus
| | - Guankui Wang
- The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus
| | - Fangfang Chen
- The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus; Department of Cardiology, China-Japan Union Hospital of Jilin University; Department of Gastrointestinal, Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University;
| | - Dmitri Simberg
- The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus
| |
Collapse
|
6
|
Ternullo S, Basnet P, Holsæter AM, Flaten GE, de Weerd L, Škalko-Basnet N. Deformable liposomes for skin therapy with human epidermal growth factor: The effect of liposomal surface charge. Eur J Pharm Sci 2018; 125:163-171. [PMID: 30300691 DOI: 10.1016/j.ejps.2018.10.005] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2018] [Revised: 10/05/2018] [Accepted: 10/06/2018] [Indexed: 12/14/2022]
Abstract
The topical administration of exogenous human epidermal growth factor (hEGF) is a promising approach for improved chronic wound therapy. To develop therapeutically superior hEGF formulation, we prepared hEGF-containing neutral (NDLs), cationic (CDLs) and anionic (ADLs) deformable liposomes (DLs), respectively, since it is expected that the liposomal surface charge can affect both the liposomal physicochemical properties, their skin penetration potential and therapeutic efficacy of liposome-associated drug. All prepared liposomes were of similar size (300-350 nm) with high hEGF load (~80% entrapment efficacy). Among the studied DLs, ADLs were found to be most promising for sustained release of hEGF, as assessed in vitro using the polyamide membrane. Ex vivo studies revealed that all DLs were excellent systems for skin therapy with hEGF and no penetration of hEGF through the full thickness human skin was detected. ADLs provided a depot exhibiting the highest hEGF retention onto the human skin surface. ADLs also revealed enhanced mitogenic activities in human fibroblasts compared to both NDLs and CDLs after 48 hrs treatment. Moreover, hEGF-containing ADLs significantly enhanced mitogenic activity in fibroblast as compared to activity of hEGF solution (positive control). Similar trends were observed in human keratinocytes after 24 hrs of treatment. We proved that the liposomal surface charge affects the therapeutic potential of hEGF-containing liposomes. hEGF-containing ADLs can be a promising nanosystem-based formulation for localized therapy of chronic wounds.
Collapse
Affiliation(s)
- Selenia Ternullo
- Drug Transport and Delivery Research Group, Department of Pharmacy, University of Tromsø The Arctic University of Norway, Universitetsveien 57, 9037 Tromsø, Norway
| | - Purusotam Basnet
- IVF Clinic, Department of Obstetrics and Gynecology, University Hospital of North Norway, Sykehusvegen 38, 9019 Tromsø, Norway; Women's Health and Perinatology Research Group, Department of Clinical Medicine, University of Tromsø The Arctic University of Norway, Universitetsveien 57, 9037 Tromsø, Norway
| | - Ann Mari Holsæter
- Drug Transport and Delivery Research Group, Department of Pharmacy, University of Tromsø The Arctic University of Norway, Universitetsveien 57, 9037 Tromsø, Norway
| | - Gøril Eide Flaten
- Drug Transport and Delivery Research Group, Department of Pharmacy, University of Tromsø The Arctic University of Norway, Universitetsveien 57, 9037 Tromsø, Norway
| | - Louis de Weerd
- Department of Plastic and Reconstructive Surgery, University Hospital of North Norway, Sykehusvegen 38, 9019 Tromsø, Norway; Research Group for Medical Imaging, Department of Clinical Medicine, University of Tromsø The Arctic University of Norway, Universitetsveien 57, 9037 Tromsø, Norway
| | - Nataša Škalko-Basnet
- Drug Transport and Delivery Research Group, Department of Pharmacy, University of Tromsø The Arctic University of Norway, Universitetsveien 57, 9037 Tromsø, Norway.
| |
Collapse
|
7
|
Riviere JE, Jaberi-Douraki M, Lillich J, Azizi T, Joo H, Choi K, Thakkar R, Monteiro-Riviere NA. Modeling gold nanoparticle biodistribution after arterial infusion into perfused tissue: effects of surface coating, size and protein corona. Nanotoxicology 2018; 12:1093-1112. [PMID: 29856247 DOI: 10.1080/17435390.2018.1476986] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
A detailed understanding of the factors governing nanomaterial biodistribution is needed to rationally design safe nanomedicines. This research details the pharmacokinetics of gold nanoparticle (AuNP) biodistribution after arterial infusion of 40 or 80 nm AuNP (1 μg/ml) into the isolated perfused porcine skin flap (IPPSF). AuNP had surface coatings consisting of neutral polyethylene glycol (PEG), anionic lipoic acid (LA), or cationic branched polyethylenimine (BPEI). Effect of a porcine plasma corona (PPC) on 40 nm BPEI and PEG-AuNP were assessed in the IPPSF. Au concentrations were determined by ICP/MS and arterial to venous concentration-time profiles were analyzed over 8 hr (4 hr infusion, 4 hr washout) using a two-compartment pharmacokinetic model. IPPSF viability and vascular function were assessed by change in glucose utilization, vascular resistance, or weight gain after perfusion. All AuNP demonstrated some degree of AuNP arterial extraction and skin flap retention, as well as enhanced kinetic parameters of tissue uptake; with BPEI-AuNP consistently having the greatest biodistribution even with a PPC. Toxicological effects were not detected. Transmission electron microscopy confirmed intracellular uptake of AuNP. These studies paralleled previous in vitro cell culture studies using the same AuNP in human endothelial and renal proximal tubule cells, hepatocytes, keratinocytes, showing BPEI-AuNP having the greatest uptake, although the presence of a PPC did not reduce IPPSF biodistribution as in the cell culture studies. These findings clearly indicate arterial to the venous extraction of AuNP after infusion with the magnitude of extraction being greatest with the BPEI surface coating and provide data and model structure necessary to construct the whole body physiologically based pharmacokinetic models capable of utilizing available in vitro data.
Collapse
Affiliation(s)
- Jim E Riviere
- a Institute of Computational Comparative Medicine (ICCM), Kansas State University , Manhattan , KS , USA.,b Department of Anatomy and Physiology , Kansas State University , Manhattan , KS , USA
| | - Majid Jaberi-Douraki
- a Institute of Computational Comparative Medicine (ICCM), Kansas State University , Manhattan , KS , USA.,b Department of Anatomy and Physiology , Kansas State University , Manhattan , KS , USA.,c Department of Mathematics , Kansas State University , Manhattan , KS , USA
| | - James Lillich
- b Department of Anatomy and Physiology , Kansas State University , Manhattan , KS , USA
| | - Tahmineh Azizi
- a Institute of Computational Comparative Medicine (ICCM), Kansas State University , Manhattan , KS , USA.,b Department of Anatomy and Physiology , Kansas State University , Manhattan , KS , USA.,c Department of Mathematics , Kansas State University , Manhattan , KS , USA
| | - Hyun Joo
- a Institute of Computational Comparative Medicine (ICCM), Kansas State University , Manhattan , KS , USA.,b Department of Anatomy and Physiology , Kansas State University , Manhattan , KS , USA
| | - Kyoungju Choi
- b Department of Anatomy and Physiology , Kansas State University , Manhattan , KS , USA.,d Nanotechnology Innovation Center of Kansas State (NICKS), Kansas State University , Manhattan , KS , USA
| | - Ravi Thakkar
- b Department of Anatomy and Physiology , Kansas State University , Manhattan , KS , USA.,d Nanotechnology Innovation Center of Kansas State (NICKS), Kansas State University , Manhattan , KS , USA
| | - Nancy A Monteiro-Riviere
- b Department of Anatomy and Physiology , Kansas State University , Manhattan , KS , USA.,d Nanotechnology Innovation Center of Kansas State (NICKS), Kansas State University , Manhattan , KS , USA
| |
Collapse
|
8
|
Abstract
The use of human organotypic models for biomedical research is experiencing a significant increase due to their biological relevance, the possibility to perform high-throughput analyses, and their cost efficiency. In the field of anti-infective research, comprising the search for novel antipathogenic treatments including vaccines, efforts have been made to reduce the use of animal models. That is due to two main reasons: unreliability of data obtained with animal models and the increasing willingness to reduce the use of animals in research for ethical reasons. Human three-dimensional (3-D) models may substitute and/or complement in vivo studies, to increase the translational value of preclinical data. Here, we provide an overview of recent studies utilizing human organotypic models, resembling features of the cervix, intestine, lungs, brain, and skin in the context of anti-infective research. Furthermore, we focus on the future applications of human skin models and present methodological protocols to culture human skin equivalents and human skin explants.
Collapse
|
9
|
Ternullo S, de Weerd L, Holsæter AM, Flaten GE, Škalko-Basnet N. Going skin deep: A direct comparison of penetration potential of lipid-based nanovesicles on the isolated perfused human skin flap model. Eur J Pharm Biopharm 2017; 121:14-23. [PMID: 28916504 DOI: 10.1016/j.ejpb.2017.09.006] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Revised: 08/18/2017] [Accepted: 09/11/2017] [Indexed: 10/18/2022]
Abstract
Phospholipid-based nanocarriers are attractive drug carriers for improved local skin therapy. In the present study, the recently developed isolated perfused human skin flap (IPHSF) model was used to directly compare the skin penetration enhancing potential of the three commonly used nanocarriers, namely conventional liposomes (CLs), deformable liposomes (DLs) and solid lipid nanoparticles (SLNs). Two fluorescent markers, calcein (hydrophilic) or rhodamine (lipophilic), were incorporated individually in the three nanosystems. The nanocarrier size ranged between 200 and 300nm; the surface charge and entrapment efficiency for both markers were dependent on the lipid composition and the employed surfactant. Both carrier-associated markers could not penetrate the full thickness human skin, confirming their suitability for dermal drug delivery. CLs exhibited higher retention of both markers on the skin surface compared to DLs and SLNs, indicating a depo formation. DLs and SLNs enabled the deeper penetration of the two markers into the skin layers. In vitro and ex vivo skin penetration studies performed on the cellophane membrane and full thickness pig/human skin, respectively, confirmed the findings. In conclusion, efficient dermal drug delivery can be achieved by optimization of a lipid nanocarrier on the suitable skin-mimicking model to assure system's accumulation in the targeted skin layer.
Collapse
Affiliation(s)
- Selenia Ternullo
- Drug Transport and Delivery Research Group, Department of Pharmacy, University of Tromsø The Arctic University of Norway, Universitetsveien 57, 9037 Tromsø, Norway.
| | - Louis de Weerd
- Department of Plastic and Reconstructive Surgery, University Hospital of North Norway, Sykehusvegen 38, 9019 Tromsø and Department of Clinical Medicine, University of Tromsø The Arctic University of Norway, Universitetsveien 57, 9037 Tromsø, Norway.
| | - Ann Mari Holsæter
- Drug Transport and Delivery Research Group, Department of Pharmacy, University of Tromsø The Arctic University of Norway, Universitetsveien 57, 9037 Tromsø, Norway.
| | - Gøril Eide Flaten
- Drug Transport and Delivery Research Group, Department of Pharmacy, University of Tromsø The Arctic University of Norway, Universitetsveien 57, 9037 Tromsø, Norway.
| | - Nataša Škalko-Basnet
- Drug Transport and Delivery Research Group, Department of Pharmacy, University of Tromsø The Arctic University of Norway, Universitetsveien 57, 9037 Tromsø, Norway.
| |
Collapse
|
10
|
Abstract
OBJECTIVE Topical delivery of drugs is an alternative to oral administration, often with similar efficacy but potentially a more favorable tolerability profile. However, topical formulations need to be able to penetrate the skin and permeate to the target areas in quantities sufficient to exert a therapeutic effect. Many factors can affect this process, including the physicochemical properties of the drug, the formulation used, and the site and mode of application. It is believed that measurement of drug concentrations at the sites of action may be an indicator of their likely efficacy. This review addresses these issues, with reference to topically administered diclofenac in osteoarthritis. METHODS Articles relevant to this review were identified after a systematic search of Medline and Embase, using the key words "diclofenac", "topical administration" and "osteoarthritis" in the search strategy. RESULTS The sparse data available indicate that topical diclofenac can penetrate and permeate to deeper tissues, with a lower plasma to tissue ratio than oral diclofenac. The tissue diclofenac levels after topical delivery are sustained over time (at least several hours). However, there is not enough data to establish how diclofenac levels in the joint compare with IC50 levels (50% of the maximum inhibition of prostaglandin synthesis) established following oral administration. CONCLUSIONS After topical application, diclofenac can penetrate the skin and permeate to deeper tissues, where it reaches a concentration that appears to be sufficient to exert a therapeutic effect. More robust methods are required for in vivo characterization to better estimate the clinical efficacy of topically applied drugs.
Collapse
Affiliation(s)
- Martina Hagen
- a GlaxoSmithKline Consumer Healthcare , Nyon , Switzerland
| | - Mark Baker
- a GlaxoSmithKline Consumer Healthcare , Nyon , Switzerland
| |
Collapse
|